SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123248
Filing Date
2024-11-07
Accepted
2024-11-07 16:02:05
Documents
75
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-20240930.htm   iXBRL 10-Q 1888933
2 EX-10.3 aldx-ex10_3.htm EX-10.3 187837
3 EX-10.4 aldx-ex10_4.htm EX-10.4 80105
4 EX-31.1 aldx-ex31_1.htm EX-31.1 16323
5 EX-31.2 aldx-ex31_2.htm EX-31.2 16569
6 EX-32.1 aldx-ex32_1.htm EX-32.1 11793
7 GRAPHIC img130890548_0.jpg GRAPHIC 79815
  Complete submission text file 0000950170-24-123248.txt   7489439

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20240930.xsd EX-101.SCH 1000308
77 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20240930_htm.xml XML 1002524
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 241435402
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)